In the ALK-rearranged NSCLC setting, liquid biopsy, mainly through ctDNA [73], progressively gained a routine application in the monitoring response to treatment and in early detection of tumor remission and molecular resistance to ALK-i. The gene discussed is ALK; the disease is neoplasm.